Key highlights
- TREMFYA® shows durable remission in Crohn's disease at 96 weeks.
- The study involved Phase 3 GRAVITI, GALAXI 2, and GALAXI 3 trials.
- Patients received subcutaneous or intravenous induction followed by maintenance doses.
- Safety data aligns with TREMFYA®'s established profile.
Study Overview
Johnson & Johnson presented 96-week data from the Phase 3 GRAVITI, GALAXI 2, and GALAXI 3 studies, highlighting TREMFYA®'s efficacy in treating moderately to severely active Crohn's disease.
Treatment Regimen
Patients received either 400 mg subcutaneous or 200 mg intravenous induction, followed by maintenance doses of 100 mg every eight weeks or 200 mg every four weeks.
Clinical Outcomes
At Week 96, high rates of clinical remission, endoscopic response, endoscopic remission, and deep remission were observed, with clinical remission rates reaching up to 93.4%.
Safety Profile
Safety data through 96 weeks were consistent with TREMFYA®'s established safety profile, supporting its long-term use in Crohn's disease management.
